Mesenchymal Stem Cells (MSCs) Explained: The Workhorse of Regenerative Medicine

What is the cell type the patient keeps encountering on every clinic page, every published study, and every patient-information portal? Saturday morning at the study window seat, coffee gone cool in the second refill, the patient has a journal article printed at the top and a notepad with three terms circled. MSC. Mesenchymal stem cell. Mesenchymal stromal cell. The clinic the patient called Tuesday used the first abbreviation. The clinic across town used the third. The published article uses the second and the third interchangeably in different paragraphs. Three names. One cell type, mostly. The mostly is where the patient has stopped to read more carefully.

This guide is for that morning. It explains what MSCs are, why they show up in nearly every conversation about cell-based therapy, what they can and cannot do, and how the published research and the international scientific societies describe them in current language.

Where MSCs Come From and Why They Are Used Clinically

MSCs are a type of adult stem or progenitor cell found in many tissues throughout the body. The most clinically familiar sources are bone marrow, adipose tissue, and umbilical cord, with smaller populations identified in dental pulp, placenta, synovial membrane, and several other tissues. The cells share a common set of properties that the International Society for Cell and Gene Therapy, in its long-standing position statements and the May 2025 update, defines through surface marker profile and functional assays.

Two reasons drive the clinical interest in MSCs:

They are accessible. Bone marrow harvest, adipose lipoaspirate, and umbilical cord tissue collection are all procedures that can be performed in clinical or banking settings without the ethical and regulatory complexity of embryonic stem cell sourcing.
They are versatile. MSCs have differentiation capacity that includes bone, cartilage, and fat lineages, and they exert biological effects on surrounding tissue that go beyond direct cell replacement.

The combination of accessibility and versatility is what makes MSCs the cell type that shows up most frequently in regenerative-medicine clinical practice. The label “workhorse” is not marketing. It is a fair description of where most patient-facing cell-based therapy operates today, both in routine clinical settings and in trial protocols documented through ClinicalTrials.gov and the published literature.

What Makes MSCs Therapeutically Interesting

The therapeutic premise behind MSCs runs along three lines, each with different levels of supporting research and different implications for the patient considering treatment:

Direct differentiation, where the cells become local tissue (bone, cartilage, fat) at the injection site
Paracrine activity, where the cells secrete cytokines, chemokines, growth factors, and signaling molecules that influence surrounding tissue
Immunomodulation, where the cells interact with immune cells to dampen excessive inflammation or modulate immune response

The differentiation premise is the oldest and the one most patients hear first. The paracrine and immunomodulatory premises have grown in research importance over the past decade, and they often explain clinical effects that pure differentiation cannot.

The published literature on NIH PubMed Central documents the mechanisms in detail, with reviews describing how MSC immunomodulation is mediated by direct cell-to-cell contact and by the secretion of soluble factors that influence both innate and adaptive immune cells. The cell type’s biology is more complex than the early “stem cells become tissue” framing the consumer market still tends to lean on, and patients reading current literature will encounter mechanism descriptions that go beyond simple replacement.

How MSC Differentiation Capacity Shapes Treatment Use

What MSCs can become matters for treatment design. The ISCT minimal criteria specify the in vitro lineages MSCs must demonstrate: differentiation into osteoblasts, adipocytes, and chondroblasts under standard culture conditions. The criteria define what counts as an MSC for clinical and research purposes. The clinical translation is narrower than the laboratory potential might suggest.

Three practical points worth carrying:

In the body, MSCs do not always differentiate at the rate or scale the in vitro assays suggest. Local environment, growth factors, and tissue context shape what the cells do once injected.
Injection site biology matters. MSCs delivered to a knee joint behave differently than the same cells delivered to a tendon, a wound bed, or systemic circulation.
Differentiation may be a smaller part of the clinical effect than paracrine and immunomodulatory activity, particularly for inflammatory conditions where the cells’ interaction with immune cells often tends to produce response patterns the published research describes.

A patient hearing a clinic describe MSC therapy as a process where the cells “become new cartilage” or “rebuild the joint” is hearing a simplified version of a more complex biology. The simplified version is not always wrong, but it leaves out the paracrine and immunomodulatory dimensions that current research considers central to the therapeutic effect.

Why Immunomodulation Is the Less-Discussed MSC Mechanism

Immunomodulation rarely makes it into clinic marketing the way “stem cells regenerate tissue” does, partly because the mechanism is less photogenic and partly because it requires more biological context to explain. The mechanism, however, is part of what supports MSC use in conditions where the underlying problem is immune dysregulation rather than purely structural damage.

The NIH PubMed Central reviews on MSC immunomodulation describe several pathways:

Direct contact with immune cells, where MSC surface molecules interact with T cells, B cells, and other immune populations to dampen activation
Paracrine secretion of cytokines and chemokines that modulate immune cell behavior at distance
Effects on macrophage polarization, where MSCs shift macrophage activity from pro-inflammatory toward resolution-oriented states
Modulation of dendritic cell maturation and antigen presentation

Conditions where immunomodulation is part of the MSC therapeutic premise include autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, graft-versus-host disease in the post-transplant setting, and certain inflammatory conditions where the immune response itself drives the tissue damage. The December 2024 FDA approval of an allogeneic bone-marrow MSC product for pediatric steroid-refractory graft-versus-host disease, documented in the ISCT MSC committee statements, is one of the most concrete examples of an immunomodulation-based MSC therapy that has cleared the full regulatory pathway in the United States.

For the patient, the implication is that asking what mechanism the clinic is invoking matters. A clinic that describes MSC therapy primarily through differentiation language for a condition where immunomodulation is the more established mechanism may be operating from older framing. A clinic that describes both mechanisms and acknowledges the limits of each is operating closer to current literature.

MSC Sources Compared: Bone Marrow, Adipose, and Umbilical Cord

Three sources dominate clinical practice. They differ in cell yield, harvest experience, regulatory profile, and the published response data:

Source	Harvest	Cell yield	Common applications	Regulatory note
Bone marrow	Iliac crest aspiration	Lower per volume	Joints, tendons, wound, GVHD trials	Section 361 for autologous concentrate; Section 351 for expansion
Adipose	Lipoaspiration, abdomen or flank	Higher per volume	Joints, soft tissue, cosmetic	Same regulatory framework, with specific minimal-manipulation considerations
Umbilical cord	Donor cord tissue at birth	Bank-supplied	Trial settings, allogeneic indications	Section 351 in most non-relative donor settings

A practical comparison the patient can carry:

Bone marrow concentrate has the longest clinical track record in orthopedic settings.
Adipose-derived cells are easier to harvest in larger volumes and have grown common over the past decade.
Umbilical cord-derived products are subject to stricter regulatory pathways when crossing from autologous to non-relative allogeneic territory, and patient-facing claims about their potency often outpace the regulatory standing of the products being marketed.

The ISSCR Guide to Stem Cell Treatments, in its current patient-facing version, describes these source distinctions in language written for patients rather than clinicians, and it is one of the better starting points for a patient who wants the source comparison without the marketing layer.

Which Clinical Applications Have Documented Patient Response

The clinical application list for MSCs is long. The depth of supporting research varies across it. A short calibration helps the patient sort:

Strongest documented response in trial settings: knee osteoarthritis, certain tendon conditions, graft-versus-host disease in the post-transplant setting
Active research with growing data: autoimmune conditions including rheumatoid arthritis and Crohn’s disease, certain spinal cord and stroke applications, tissue engineering applications
Active research with mixed or early data: cardiac applications, certain neurodegenerative conditions, broad cosmetic anti-aging claims
Marketing claims that outpace research: most “anti-aging” cell therapy, broad systemic-rejuvenation claims, conditions where the mechanism does not align with established MSC biology

The patient comparing clinic claims to the published literature is comparing a fast-moving marketing field to a slower-moving research field. The two do not always line up. When they do, the patient is reading marketing that matches the science. When they do not, the patient has identified a question the consultation should answer rather than evade.

Saturday morning at the study window seat ends with the third coffee, the journal article folded, and the notepad page filled. The three terms the patient circled at the start now have meanings that hold across the three clinic conversations. MSC, mesenchymal stem cell, and mesenchymal stromal cell describe a cell type with three principal mechanisms and three principal sources, alongside a clinical-application list with calibrated levels of supporting research. The vocabulary the clinics use is the same. The principle behind the vocabulary, when read against the current scientific consensus the ISCT and ISSCR documents lay out, often tends to clarify which clinic conversation matches the science and which one does not.

Important note on regenerative therapy: No regenerative therapy is fully predictable in outcome, and any guidance that promises otherwise overstates what current evidence supports. The realistic question for a patient considering treatment is what level of preliminary or emerging evidence the patient and clinician find sufficient and what specific practices keep the decision aligned with that evidence base.

Sources: